Reference priceBRL R$3,412.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Halaven |
|---|---|
| Manufacturer | EISAI INC |
| Prescription required | Yes |
Halaven 0.5mg/ml 2ml(eribulin mesylate)
eribulin mesylate
Description
Halaven 0.5mg/ml 2ml(eribulin mesylate) is a medicine catalog record in the MediPriceHub database. Active ingredient: eribulin mesylate. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: EISAI INC. Therapeutic category: Medicine Library > Oncology Medicines > Liposarcoma drugs. Pack information: 1 / 2 (0.5 ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. 1.1 Metastatic Breast Cancer Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [see Clinical Studies ]. 1.2 Liposarcoma Eribulin mesylate injection is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen [see Clinical Studies ] .How to Use
Use eribulin mesylate under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: eribulin mesylate. Pack size: 1 / 2 (0.5 ). Pack unit: box. Manufacturer: EISAI INC. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Liposarcoma drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.Esta informação é apenas para referência. Consulte um profissional de saúde antes de usar qualquer medicamento.